<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:50:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4004714" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4004714</identifier>
        <datestamp>2015-05-01</datestamp>
        <setSpec>pheelsevier</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="brief-report">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Allergy Clin Immunol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Allergy Clin. Immunol</journal-id>
              <journal-title-group>
                <journal-title>The Journal of Allergy and Clinical Immunology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0091-6749</issn>
              <issn pub-type="epub">1097-6825</issn>
              <publisher>
                <publisher-name>American Academy of Allergy, Asthma &amp; Immunology. Published by Mosby, Inc.</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4004714</article-id>
              <article-id pub-id-type="pmcid">PMC4004714</article-id>
              <article-id pub-id-type="pmc-uid">4004714</article-id>
              <article-id pub-id-type="pmid">24373352</article-id>
              <article-id pub-id-type="publisher-id">S0091-6749(13)01767-3</article-id>
              <article-id pub-id-type="doi">10.1016/j.jaci.2013.11.009</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Plasminogen activator inhibitor-1 in sputum and nasal lavage fluids increases in asthmatic patients during common colds</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Cho</surname>
                    <given-names>Seong H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <email>seong-cho@northwestern.edu</email>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Hong</surname>
                    <given-names>Seung J.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Haimei</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Habib</surname>
                    <given-names>Ali</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>Cho</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Sun H.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Kang</surname>
                    <given-names>Joseph</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Ward</surname>
                    <given-names>Theresa</given-names>
                  </name>
                  <degrees>RN</degrees>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Boushey</surname>
                    <given-names>Homer A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Schleimer</surname>
                    <given-names>Robert P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Avila</surname>
                    <given-names>Pedro C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>a</label>Division of Allergy-Immunology, Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Ill</aff>
              <aff id="aff2"><label>b</label>Division of Rheumatology, Department of Medicine, Kyung Hee University School of Medicine, Seoul, Korea</aff>
              <aff id="aff3"><label>c</label>Department of Preventive Medicine, Northwestern Feinberg School of Medicine, Chicago, Ill</aff>
              <aff id="aff4"><label>d</label>Department of Medicine, Cardiovascular Research Institute, University of California at San Francisco, San Francisco, Calif</aff>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>12</month>
                <year>2013</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="ppub">
                <month>5</month>
                <year>2014</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>12</month>
                <year>2013</year>
              </pub-date>
              <volume>133</volume>
              <issue>5</issue>
              <fpage>1465</fpage>
              <lpage>1467.e2</lpage>
              <permissions>
                <copyright-statement>Copyright © 2013 American Academy of Allergy, Asthma &amp; Immunology. Published by Mosby, Inc. All rights reserved.</copyright-statement>
                <copyright-year>2013</copyright-year>
                <copyright-holder>American Academy of Allergy, Asthma &amp; Immunology</copyright-holder>
                <license>
                  <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
                </license>
              </permissions>
            </article-meta>
          </front>
          <body>
            <p content-type="salutation">To the Editor:</p>
            <p id="p0010">The possibility that recurrent asthma exacerbations associated with common colds promote airway remodeling is suggested by the finding of accelerated lung function decline over time in patients with asthma who have frequent exacerbations.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> The presumed cause of loss of lung function in asthma is airway remodeling. One of the inflammatory mediators thought to promote airway remodeling is plasminogen activator inhibitor-1 (PAI-1), which inhibits both the fibrinolytic system and the matrix metalloproteinase system.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> We have previously reported that PAI-1 is highly expressed in patients with fatal asthma<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> and that elevated plasma levels of PAI-1 are associated with diminished forced vital capacity.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> We here report that common colds are associated with increased PAI-1 production in airways of asthmatic subjects.</p>
            <p id="p0015">Fifty-two asthmatic subjects, 9 subjects with allergic rhinitis, and 14 healthy controls were evaluated within 1 to 3 days of cold onset (visit 1), then between day 5 and 7 of cold symptoms (visit 2), and at 6 weeks or longer thereafter to assess baseline status (visit 3). At each visit, induced sputum and nasal lavage fluid (NLF) samples were collected and spirometry performed as described previously.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The Virochip<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> was used to detect viruses at visit 1. Allergy skin testing was performed at visit 3 to assess atopy. This study was approved by the Internal Review Boards of the University of California at San Francisco and Northwestern University. PAI-1 concentrations in sputum and NLF were determined by using ELISA (AssayPro, St Charles, Mo). All statistical analyses were performed with the Prism software, version 5 (GraphPad, San Diego, Calif). First, all the 3 groups were compared by using the Kruskal-Wallis test, and then 2-group comparisons were done with the Mann-Whitney <italic>U</italic> test. Serial measurements were analyzed with the Friedman rank test and paired comparisons by the Wilcoxon paired test. A <italic>P</italic> value of less than .05 was considered statistically significant.</p>
            <p id="p0020">Clinical characteristics of subjects showed expected differences (<xref rid="tbl1" ref-type="table">Table I</xref>
). A higher proportion of allergic rhinitis and asthmatic subjects were atopic compared with healthy controls, and asthmatic subjects had the lowest FEV<sub>1</sub>. There were no significant differences in age and sex among the groups. The proportion of respiratory virus detection was similar between asthmatic and healthy subjects (63.4% vs 71.4%). Among the detected viruses, rhinovirus was the most prevalent in the 3 subject groups. At baseline, sputum PAI-1 levels were significantly higher in asthmatic subjects than in nonasthmatic controls (median ± interquartile range, 3.6 ± 2.6 vs 2.3 ± 2.1 ng/mL; <italic>P</italic> &lt; .02) (<xref rid="fig1" ref-type="fig">Fig 1</xref>
, <italic>A</italic>). In asthmatic patients, sputum PAI-1 levels increased significantly on day 5 to 7 compared with the baseline levels (<italic>P</italic> &lt; .05; <xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>B</italic>), whereas they did not change significantly in nonasthmatic subjects (see <xref rid="dfig1" ref-type="graphic">Fig E1</xref> in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0010">www.jacionline.org</ext-link>). Sputum PAI-1 levels in asthmatic patients with exacerbation (FEV<sub>1</sub> drop ≥10%, n = 4) were higher than in those without exacerbation (n = 17), although it was not statistically significant (6.6 vs 4.7 ng/mL on days 1-3, <italic>P</italic> = .9; 11.7 vs 4.8 ng/mL on days 5-7, <italic>P</italic> = .3). There was no significant difference in baseline NLF PAI-1 levels between asthmatic and nonasthmatic subjects (0.05 vs 0.08 ng/mL, <italic>P</italic> = .2). PAI-1 levels in NLF samples from asthmatic patients were significantly higher both at days 1 to 3 and at days 5 to 7 than at baseline (<italic>P</italic> &lt; .001 and <italic>P</italic> &lt; .01, respectively; <xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>C</italic>). Interestingly, asthmatic subjects had an early elevation in PAI-1 levels (days 1-3) in NLF samples, which was not observed in NLF samples from nonasthmatic subjects (see <xref rid="dfig2" ref-type="graphic">Fig E2</xref> in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0015">www.jacionline.org</ext-link>). To investigate whether rhinovirus, the most prevalent common cold virus, induces airway epithelial cells from asthmatic subjects to produce PAI-1, we obtained and cultured primary nasal epithelial cells in submerged medium from 7 asthmatic subjects, and treated them with either human rhinovirus (HRV) serotype 16 at multiplicity of infection of 1 or vehicle control for 48 hours. PAI-1 levels in the supernatants of infected cultures from asthmatic patients increased significantly compared with noninfected cultures (<italic>P</italic> &lt; .05; <xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>D</italic>).<table-wrap position="float" id="tbl1"><label>Table I</label><caption><p>Demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Asthma (n = 52)</th><th>Allergic rhinitis (n = 9)</th><th>Healthy control (n = 14)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Age (y), median (IQR)</td><td align="char">32.5 (16.3)</td><td align="char">35.0 (24.5)</td><td align="char">29.5 (7.0)</td><td align="char">.184<xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref></td></tr><tr><td>Sex: female, n (%)</td><td align="char">40 (77)</td><td align="char">7 (78)</td><td align="char">8 (57)</td><td align="char">.315<xref rid="tbl1fndagger" ref-type="table-fn">†</xref></td></tr><tr><td>Atopy, n (%)</td><td align="char"><bold>38 (73)</bold></td><td align="char"><bold>9 (100)</bold></td><td align="char">2 (14)</td><td align="char"><bold>&lt;.0001</bold><xref rid="tbl1fndagger" ref-type="table-fn">†</xref></td></tr><tr><td>Race, n (%)</td><td/><td/><td/><td/></tr><tr><td> White</td><td align="char">33 (63)</td><td align="char">5 (56)</td><td align="char">13 (93)</td><td/></tr><tr><td> Black</td><td align="char">6 (12)</td><td align="char">1 (11)</td><td align="char">0 (0)</td><td/></tr><tr><td> Hispanic</td><td align="char">5 (10)</td><td align="char">1 (11)</td><td align="char">0 (0)</td><td/></tr><tr><td> Others</td><td align="char">8 (15)</td><td align="char">2 (22)</td><td align="char">1 (7)</td><td/></tr><tr><td>Baseline FEV<sub>1</sub> % predicted</td><td><bold>92.2</bold><xref rid="tbl1fnddagger" ref-type="table-fn">‡</xref></td><td>109.0</td><td>104.0</td><td align="char"><bold>.0008</bold><xref rid="tbl1fnlowast" ref-type="table-fn">*</xref></td></tr><tr><td>Virus detection, n (%)</td><td/><td/><td/><td/></tr><tr><td> Rhinovirus only</td><td align="char">22 (42)</td><td align="char">3 (33)</td><td align="char">7 (50)</td><td/></tr><tr><td> Coronavirus only</td><td align="char">6 (12)</td><td align="char">0 (0)</td><td align="char">3 (21)</td><td/></tr><tr><td> RSV only</td><td align="char">2 (4)</td><td align="char">0 (0)</td><td align="char">0 (0)</td><td/></tr><tr><td> Enterovirus only</td><td align="char">1 (2)</td><td align="char">0 (0)</td><td align="char">0 (0)</td><td/></tr><tr><td> Influenza virus only</td><td align="char">0 (0)</td><td align="char">1 (11)</td><td align="char">0 (0)</td><td/></tr><tr><td> RSV + coronavirus</td><td align="char">1 (2)</td><td align="char">0 (0)</td><td align="char">0 (0)</td><td/></tr><tr><td> RSV + influenza virus</td><td align="char">1 (2)</td><td align="char">0 (0)</td><td align="char">0 (0)</td><td/></tr><tr><td> Any virus</td><td align="char">33 (63)</td><td align="char">4 (44)</td><td align="char">10 (71)</td><td align="char">.177<xref rid="tbl1fndagger" ref-type="table-fn">†</xref></td></tr><tr><td>Current asthma control meds, n (%)</td><td/><td/><td/><td/></tr><tr><td> ICS only</td><td align="char">8 (15)</td><td/><td/><td/></tr><tr><td> Singular only</td><td align="char">1 (2)</td><td/><td/><td/></tr><tr><td> ICS + LABA</td><td align="char">6 (12)</td><td/><td/><td/></tr><tr><td> ICS + LABA + others</td><td align="char">4 (8)</td><td/><td/><td/></tr><tr><td> No medications</td><td align="char">33 (63)</td><td/><td/><td/></tr><tr><td>Nasal steroids, n (%)</td><td align="char">9 (17)</td><td align="char">0 (0)</td><td/><td/></tr></tbody></table><table-wrap-foot><fn><p><italic>ICS</italic>, Inhaled corticosteroids; <italic>IQR</italic>, interquartile range; <italic>LABA</italic>, long-acting β-2-adrenergic receptor agonists; <italic>meds</italic>, medications; <italic>RSV</italic>, respiratory syncytial virus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>∗</label><p id="ntpara0020"><italic>P</italic> from the Kruskal-Wallis test comparing all 3 groups.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fndagger"><label>†</label><p id="ntpara0025"><italic>P</italic> from the χ<sup>2</sup> test comparing all 3 groups.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnddagger"><label>‡</label><p id="ntpara0030">Asthma severity based on baseline FEV<sub>1</sub> (spirometry was available in 44 patients out of 52): FEV<sub>1</sub> is 80% or more in 86.4% (n = 38), 60% to 79% in 13.6% (n = 6), and less than 60% in 0% of asthmatic patients.</p></fn></table-wrap-foot></table-wrap><fig id="fig1"><label>Fig 1</label><caption><p>PAI-1 in airway secretions during a common cold. Baseline sputum PAI-1 levels were measured in asthmatic and nonasthmatic subjects <bold>(A</bold>, <italic>red circles</italic>—allergic rhinitis; <italic>green triangles</italic>—healthy controls<bold>)</bold>. Both sputum <bold>(B)</bold> and nasal lavage <bold>(C)</bold> PAI-1 levels were also measured during colds in asthmatic patients. <bold>D,</bold> PAI-1 levels in supernatants of nasal epithelial cells from asthmatic patients 48 hours after human rhinovirus <italic>(HRV)</italic> infection.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p>
            <p id="p0025">Our results show that at baseline, sputum PAI-1 levels are significantly higher in asthmatic patients versus nonasthmatic controls. In addition, the common cold increased PAI-1 levels in upper and lower airways of asthmatic subjects but not in control subjects. Lastly, <italic>in vitro</italic>, HRV induced epithelial production of PAI-1. Our data on increased sputum PAI-1 levels at baseline in asthma are similar to previous reports.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Previous studies suggest that PAI-1 may be related to airway obstruction by not only extracellular matrix deposition in the airway wall but also intraluminal fibrin deposition.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> This may explain at least in part the mechanism by which frequent exacerbations may cause progressive airway obstruction in a subset of patients, and why reduction in FEV<sub>1</sub> is associated with a history of frequent exacerbations in asthmatic patients.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> A similar study of asthmatic subjects with cold showed that there was a very high level of fibrinogen in induced sputum on day 4.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> We hypothesize that this highly elevated fibrinogen level in airways of asthmatic subjects can potentiate conversion to fibrin, which is not degraded because of the elevated local PAI-1 level, an occurrence that may lead to the airway obstruction. Although we could not find a negative correlation between sputum PAI-1 levels and lung function due to the small sample size, we found that 2 patients with very high sputum PAI-1 level on days 1 to 3 and days 5 to 7 (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>B</italic>) were among 4 patients who had significant asthma exacerbation with FEV<sub>1</sub> drop of 10% or more. It would be interesting to conduct further studies on this observation. A recent study showed that sputum levels of PAI-1 were significantly higher in patients with a longer duration than in those with a shorter duration of asthma.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Our results raise the hypothesis that repeated respiratory viral infections may lead to repeated transient increases in airway PAI-1 levels in susceptible asthmatic patients, which over several years could lead to accelerated remodeling and progressive airway obstruction.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib8" ref-type="bibr">8</xref>
</p>
            <p id="p0030">In summary, this study demonstrates that lower airway PAI-1 levels are higher in asthmatic subjects than in healthy subjects and a common cold further increases upper and lower airway PAI-1 levels in asthmatic subjects. These results may explain the association between recurrent exacerbations and persistent lower airway obstruction. Further studies are needed to understand whether elevated PAI-1 levels lead to the accumulation of fibrin and extracellular matrix in airways of asthmatic patients.</p>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McDonald</surname>
                      <given-names>V.M.</given-names>
                    </name>
                    <name>
                      <surname>Gibson</surname>
                      <given-names>P.G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Exacerbations of severe asthma</article-title>
                  <source>Clin Exp Allergy</source>
                  <volume>42</volume>
                  <year>2012</year>
                  <fpage>670</fpage>
                  <lpage>677</lpage>
                  <pub-id pub-id-type="pmid">22515389</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ma</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Paek</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Oh</surname>
                      <given-names>C.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation</article-title>
                  <source>Clin Exp Allergy</source>
                  <volume>39</volume>
                  <year>2009</year>
                  <fpage>1136</fpage>
                  <lpage>1144</lpage>
                  <pub-id pub-id-type="pmid">19438580</pub-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cho</surname>
                      <given-names>S.H.</given-names>
                    </name>
                    <name>
                      <surname>Tam</surname>
                      <given-names>S.W.</given-names>
                    </name>
                    <name>
                      <surname>Demissie-Sanders</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Filler</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Oh</surname>
                      <given-names>C.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma</article-title>
                  <source>J Immunol</source>
                  <volume>165</volume>
                  <year>2000</year>
                  <fpage>3154</fpage>
                  <lpage>3161</lpage>
                  <pub-id pub-id-type="pmid">10975829</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cho</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Lyttle</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Harris</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Daley</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Grammer</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma</article-title>
                  <source>Ann Allergy Asthma Immunol</source>
                  <volume>106</volume>
                  <year>2011</year>
                  <fpage>371</fpage>
                  <lpage>377</lpage>
                  <pub-id pub-id-type="pmid">21530867</pub-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kistler</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Avila</surname>
                      <given-names>P.C.</given-names>
                    </name>
                    <name>
                      <surname>Rouskin</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Ward</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Yagi</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity</article-title>
                  <source>J Infect Dis</source>
                  <volume>196</volume>
                  <year>2007</year>
                  <fpage>817</fpage>
                  <lpage>825</lpage>
                  <pub-id pub-id-type="pmid">17703411</pub-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miyamoto</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hattori</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Senoo</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Onari</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Iwamoto</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Kanehara</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice</article-title>
                  <source>Am J Physiol Lung Cell Mol Physiol</source>
                  <volume>301</volume>
                  <year>2011</year>
                  <fpage>L908</fpage>
                  <lpage>L916</lpage>
                  <pub-id pub-id-type="pmid">21926267</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pampuch</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Kowal</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Bodzenta-Lukaszyk</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Di Castelnuovo</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Chyczewski</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Donati</surname>
                      <given-names>M.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients</article-title>
                  <source>Allergy</source>
                  <volume>61</volume>
                  <year>2006</year>
                  <fpage>234</fpage>
                  <lpage>238</lpage>
                  <pub-id pub-id-type="pmid">16409202</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>S.H.</given-names>
                    </name>
                    <name>
                      <surname>Eren</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Vaughan</surname>
                      <given-names>D.E.</given-names>
                    </name>
                    <name>
                      <surname>Schleimer</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>S.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma</article-title>
                  <source>Am J Respir Cell Mol Biol</source>
                  <volume>46</volume>
                  <year>2012</year>
                  <fpage>842</fpage>
                  <lpage>846</lpage>
                  <pub-id pub-id-type="pmid">22323366</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>E.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>New human rhinovirus species and their significance in asthma exacerbation and airway remodeling</article-title>
                  <source>Immunol Allergy Clin North Am</source>
                  <volume>30</volume>
                  <year>2010</year>
                  <fpage>541</fpage>
                  <lpage>552</lpage>
                  <pub-id pub-id-type="pmid">21029937</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pizzichini</surname>
                      <given-names>M.M.</given-names>
                    </name>
                    <name>
                      <surname>Pizzichini</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Efthimiadis</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Chauhan</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Johnston</surname>
                      <given-names>S.L.</given-names>
                    </name>
                    <name>
                      <surname>Hussack</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Asthma and natural colds: inflammatory indices in induced sputum: a feasibility study</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>158</volume>
                  <year>1998</year>
                  <fpage>1178</fpage>
                  <lpage>1184</lpage>
                  <pub-id pub-id-type="pmid">9769279</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1">
              <title>Appendix</title>
              <p id="p0040">
                <fig id="dfig1" position="anchor">
                  <label>Fig E1</label>
                  <caption>
                    <p>Sputum PAI-1 levels of nonasthmatic subjects (healthy controls, <italic>green upward triangle</italic>; allergic rhinitis, <italic>red downward triangle</italic>) on days 1 to 3 and days 5 to 7 of the common cold onset were compared with those at baseline visit (Wilcoxon paired test, <italic>red lines</italic> indicate median value, <italic>P</italic> &gt; .05).</p>
                  </caption>
                  <graphic xlink:href="fx1_lrg"/>
                </fig>
                <fig id="dfig2" position="anchor">
                  <label>Fig E2</label>
                  <caption>
                    <p>Nasal lavage fluid levels of PAI-1 of nonasthmatic subjects (healthy controls, <italic>green upward triangle</italic>; allergic rhinitis, <italic>red downward triangle</italic>) on days 1 to 3 and days 5 to 7 of the common cold onset were compared with those at baseline visit (Wilcoxon paired test, <italic>P</italic> &gt; .05).</p>
                  </caption>
                  <graphic xlink:href="fx2_lrg"/>
                </fig>
              </p>
            </sec>
            <ack id="ack0010">
              <p>We are grateful for the assistance provided by Jane Liu, Il-Soo Kim, and Joshua Adonai.</p>
            </ack>
            <fn-group>
              <fn id="d32e719">
                <p id="ntpara0010">This study was supported by the <funding-source id="gs1">American Heart Association</funding-source> (to S.H.C.) and <funding-source id="gs2">Ernest Bazley Fund</funding-source> (to S.H.C., P.C.A., and R.P.S.); the <funding-source id="gs3">Allergy and Asthma Foundation of America</funding-source> (to P.C.A.); and NIH grants U01-AI082984 (to P.C.A.), R37-HL068546 (to R.P.S.), and R01-HL078860 (to R.P.S.). Sample collection and virus detection were funded by NIH grants P01-AI050496 and R21-AI057506 (to H.A.B. and P.C.A.).</p>
              </fn>
              <fn id="d32e731">
                <p id="ntpara0015">Disclosure of potential conflict of interest: S. H. Cho has received research support from the <funding-source id="gs4">American Heart Association (AHA)</funding-source>. T. Ward has received research support from the <funding-source id="gs5">National Institutes of Health (NIH)</funding-source>, the <funding-source id="gs6">AHA</funding-source>, and the <funding-source id="gs7">Allergy and Asthma Foundation of America (AAFA)</funding-source>. H.A. Boushey has received research support from the <funding-source id="gs8">NIH/National Heart, Lung, and Blood Institute (NHLBI) (AsthmaNet Grant)</funding-source>, <funding-source id="gs9">GSK</funding-source>, and <funding-source id="gs10">Genentech</funding-source>; has received consultant fees from Merck, GSK, Genentech, Kalbios, Pharmaxis, and Johnson &amp; Johnson; has received lecture fees from the Allergy, Asthma, and Immunology Foundation of Northern California (AAIFNC) and the Sam Sills Lecture: “Breathe California”; and receives royalties from McGraw-Hill. R. P. Schleimer has received research support from the <funding-source id="gs11">NIH</funding-source>; has received consultant fees from Intersect ENT, GSK, Allakos, and Aurasense; and has stock/stock options in Allakos. P. C. Avila has received research support from the <funding-source id="gs12">NIH/NHLBI (AsthmaNet grant)</funding-source>. The rest of the authors declare that they have no relevant conflicts of interest.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
